Ractigen Therapeutics
Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer
Trial initiated at Fudan University Shanghai Cancer Center (FUSCC) under the leadership of Leading Principal Investigator Professor Ding-Wei Ye,…